Total Payments
$2,398
2024 Payments
$369.26
Companies
13
Transactions
94
Medicare Patients
2,586
Medicare Billing
$238,474
Payment Breakdown by Category
Food & Beverage$2,196 (91.5%)
Education$202.74 (8.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,196 | 92 | 91.5% |
| Education | $202.74 | 2 | 8.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $848.98 | 48 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $808.90 | 20 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $172.44 | 6 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $142.24 | 2 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $140.06 | 4 | $0 (2024) |
| ITI, Inc. | $134.18 | 7 | $0 (2023) |
| Neuronetics, Inc. | $26.98 | 1 | $0 (2023) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.02 | 1 | $0 (2024) |
| Indivior Inc. | $23.00 | 1 | $0 (2023) |
| Lundbeck LLC | $21.65 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $369.26 | 20 | ABBVIE INC. ($235.08) |
| 2023 | $969.73 | 31 | Teva Pharmaceuticals USA, Inc. ($354.03) |
| 2022 | $706.47 | 25 | Teva Pharmaceuticals USA, Inc. ($388.00) |
| 2021 | $352.87 | 18 | Neurocrine Biosciences, Inc. ($142.24) |
All Payment Transactions
94 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/02/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $96.75 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.66 | General |
| Category: NEUROSCIENCE | ||||||
| 08/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: NEUROSCIENCE | ||||||
| 07/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.03 | General |
| Category: NEUROSCIENCE | ||||||
| 06/12/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.35 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.35 | General |
| Category: NEUROSCIENCE | ||||||
| 04/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.15 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: NEUROLOGY | ||||||
| 03/27/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Central Nervous System | ||||||
| 02/28/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Neuroscience | ||||||
| 02/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: NEUROSCIENCE | ||||||
| 02/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: Central Nervous System | ||||||
| 02/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: NEUROSCIENCE | ||||||
| 01/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Central Nervous System | ||||||
| 11/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2023 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: BH | ||||||
| 11/07/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $83.68 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2023 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $26.98 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 740 | 1,213 | $233,930 | $61,381 |
| 2022 | 14 | 819 | 1,481 | $296,275 | $84,059 |
| 2021 | 9 | 527 | 1,047 | $158,015 | $54,997 |
| 2020 | 12 | 500 | 725 | $121,342 | $38,037 |
Total Patients
2,586
Total Services
4,466
Medicare Billing
$238,474
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 136 | 320 | $63,925 | $17,111 | 26.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 106 | 108 | $37,800 | $12,271 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 115 | 249 | $43,575 | $8,053 | 18.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 43 | 44 | $15,055 | $4,559 | 30.3% |
| 90832 | Psychotherapy, 30 minutes | Office | 2023 | 42 | 72 | $13,800 | $2,860 | 20.7% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 39 | 43 | $6,575 | $2,013 | 30.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 42 | $4,170 | $1,996 | 47.9% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 25 | 29 | $5,800 | $1,950 | 33.6% |
| 90832 | Psychotherapy, 30 minutes | Facility | 2023 | 25 | 47 | $9,375 | $1,947 | 20.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 50 | 63 | $11,025 | $1,762 | 16.0% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 23 | 24 | $4,800 | $1,464 | 30.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 45 | $3,405 | $1,334 | 39.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $3,425 | $1,248 | 36.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 23 | 33 | $3,300 | $1,247 | 37.8% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 42 | 50 | $5,000 | $847.54 | 17.0% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 26 | 29 | $2,900 | $719.02 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 171 | 534 | $106,725 | $31,336 | 29.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 102 | 104 | $36,250 | $11,953 | 33.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 82 | 85 | $29,650 | $8,663 | 29.2% |
| 90832 | Psychotherapy, 30 minutes | Office | 2022 | 45 | 189 | $37,775 | $8,249 | 21.8% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 85 | 127 | $21,975 | $5,467 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 86 | $15,050 | $3,564 | 23.7% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 48 | 59 | $11,725 | $3,362 | 28.7% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Facility | 2022 | 68 | 89 | $8,700 | $2,436 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $8,800 | $2,402 | 27.3% |
About Traci Gibbs, FPMHNP-BC/LCSW
Traci Gibbs, FPMHNP-BC/LCSW is a Clinical healthcare provider based in Meridian, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1104074210.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Traci Gibbs, FPMHNP-BC/LCSW has received a total of $2,398 in payments from pharmaceutical and medical device companies, with $369.26 received in 2024. These payments were reported across 94 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($2,196).
As a Medicare-enrolled provider, Gibbs has provided services to 2,586 Medicare beneficiaries, totaling 4,466 services with total Medicare billing of $238,474. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical
- Other Specialties Psychiatric/Mental Health, Psychiatric/Mental Health
- Location Meridian, MS
- Active Since 09/03/2008
- Last Updated 09/14/2023
- Taxonomy Code 1041C0700X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1104074210
Products in Payments
- VRAYLAR (Drug) $848.98
- AUSTEDO (Drug) $246.05
- Austedo XR (Drug) $235.11
- CAPLYTA (Drug) $160.20
- INVEGA SUSTENNA (Drug) $157.56
- INGREZZA (Drug) $142.24
- UZEDY (Drug) $125.00
- REXULTI (Drug) $83.85
- ABILIFY MAINTENA (Drug) $61.36
- NEUROSTAR TMS THERAPY SYSTEM (Device) $26.98
- PERSERIS (Drug) $23.00
- TRINTELLIX (Drug) $20.00
- Auvelity (Drug) $18.29
- NUEDEXTA (Drug) $16.50
- Qelbree (Drug) $15.59
- SPRAVATO (Drug) $14.88
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.